Comparative Pharmacology
Head-to-head clinical analysis: CARBOPLATIN versus VIVIMUSTA.
Head-to-head clinical analysis: CARBOPLATIN versus VIVIMUSTA.
CARBOPLATIN vs VIVIMUSTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carboplatin forms platinum-DNA adducts, causing intrastrand crosslinks and G2/M cell cycle arrest, leading to apoptosis.
VIVIMUSTA is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
IV infusion over 15-60 minutes, target AUC 4-6 using Calvert formula (dose = target AUC × (GFR + 25)). Adults: typical initial dose 400 mg/m² every 4 weeks or AUC 5-6 every 3-4 weeks.
100 mg/m2 intravenously over 30 minutes on days 1-3 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life: 2.6-5.9 hours in adults with normal renal function. In patients with creatinine clearance <60 mL/min, half-life is prolonged (up to 17-26 hours). Clinically, dosing adjustments are required based on Calvert formula using glomerular filtration rate.
Clinical Note
moderateCarboplatin + Digoxin
"Carboplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarboplatin + Digitoxin
"Carboplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarboplatin + Deslanoside
"Carboplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarboplatin + Acetyldigitoxin
"Carboplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 12 hours (range 10-14 h) in adults with normal renal function; prolonged to 24-36 h in moderate renal impairment (CrCl 30-50 mL/min).
Renal: ~65% of platinum excreted in urine within 24 hours, primarily as unchanged carboplatin; ~32% as metabolites. Biliary/fecal excretion is minimal (<6%).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category D/X
Category C
Alkylating Agent
Alkylating Agent